Clinical

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

Researchers identified an optimal early relapse time point to incorporate into traditional risk features and formed a novel prognostic classification utilizing both static and dynamic risk.

Posters presented at the American College of Gastroenterology's (ACG's) 2023 Annual Scientific Meeting examined potential environmental risks of eosinophilic esophagitis (EoE) on the pediatric population, as well as the presence of allergic comorbidities in children diagnosed with EoE.

Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.

Panelists share their final thoughts on staying updated with the latest advancements in the field.

Experts emphasize the crucial role of swift diagnostic testing, especially through liquid biopsies.

Specialists delve into strategies for monitoring treatment response and the importance of assessing symptoms during the initial three treatment cycles.

The discussion, "Understanding Biomarkers and the Role They Play in Oncology," came during the Community Oncology Alliance Payer Exchange Summit, held October 23-24 in Reston, Virginia.

The improvement in quality of life (QOL) seen with use of sacubitril/valsartan for heart failure with preserved ejection fraction (HFpEF) could potentially result in more favorable clinical results.

Results from a retrospective, matched cohort study suggested that valvular heart disease and aortic stenosis may contribute to disparities in cardiovascular disease–related mortality in patients with rheumatoid arthritis (RA).

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s (VUMC's) department of thoracic surgery, discussed trials that helped lung cancer surgeries evolve.

Biases in care for young adults with sickle cell disease could lead to lower quality of care for these patients.

The study indicated the potential of preventative drug lists (PDLs) as a strategy for those who have high deductible health plans to address both patient access and affordability of asthma care.

The location of integration of a gene therapy has been crucial for the safety and efficacy of the treatment to cure infants with X-linked severe combined immunodeficiency.

Financial and geographic disparities contributing to elevated risk for heart disease are explored.

Robert Groves, MD, leads a panel discussion surrounding risk factors related to heart disease.

Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.

Researchers used real-world data to further validate the use of selexipag in the management of pulmonary arterial hypertension (PAH).

Panelists explore opportunities for biosimilars to manage inflammatory conditions.

FluMist Quadrivalent could become the first self-administered flu vaccine in the United States; the American Society of Reproductive Medicine updates its definition of infertility to be more inclusive; the Environmental Protection Agency moves to ban the use of a cancer-causing chemical .

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

A pooled analysis with nearly 3 years of follow-up showed better outcomes when zanubrutinib was given in the second line vs later lines of therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).